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B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell 
lymphoma (DLBCL) and Burkitt lymphoma (BL) (intermediate DLBCL/BL), is a heteroge-
neous group with some features resembling DLBCL and others resembling BL. Here, we 
report a case of intermediate DLBCL/BL in a Korean child. A 2-yr-old male was admitted 
for evaluation and management of left hip pain. Immunohistochemistry of a biopsy of the 
femur neck revealed tumor cells positive for CD20, CD10, BCL2, BCL6, and Ki67. A bone 
marrow (BM) aspirate smear revealed that 49.3% of all nucleated cells were abnormal 
lymphoid cells, composed of large- and medium-sized cells. Immunophenotyping of the 
neoplastic cells revealed positivity for CD19, CD10, CD20, and sIg lambda and negativity 
for CD34, Tdt, and myeloperoxidase (MPO). Cytogenetic and FISH analyses showed a 
complex karyotype, including t(8;14)(q24.1;q32) and IGH-MYC fusion. Intensive chemo-
therapy was initiated, including prednisone, vincristine, L-asparaginase, daunorubicin, and 
central nervous system prophylaxis with intrathecal methotrexate (MTX) and cytarabine. 
One month after the initial diagnosis, BM examination revealed the persistent of abnormal 
lymphoid cells; cerebrospinal fluid cytology, including cytospin, showed atypical lymphoid 
cells. The patient was treated again with cyclophosphamide, vincristine, prednisone, adri-
amycin, MTX, and intrathecal MTX and cytarabine. The patient died of sepsis 5 months 
after the second round of chemotherapy.
Key Words: Diffuse large B-cell lymphoma, Burkitt lymphoma, Gray zone lymphoma  
Received: June 14, 2011 
Revision received: November 4, 2011
Accepted: December 28, 2011
Corresponding author: Jeong Yeal Ahn
Department of Laboratory Medicine, 
Gachon University Gil Hospital, 1198





© The Korean Society for Laboratory Medicine.
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/3.0) which permits un-
restricted non-commercial use, distribution, and 
reproduction in any medium, provided the origi-
nal work is properly cited.
INTRODUCTION
In most cases, a better understanding of the molecular patho-
genesis underlying lymphoid malignancies has allowed for a 
pathogenesis-based approach to lymphoma classification [1, 2]. 
Improved immunophenotyping and genetic studies have in-
creased the recognition of lymphoma cases that lie on a biologic 
continuum between 2 entities [3]. Specifically, these borderline 
categories, known as “gray zone lymphoma,” “atypical Burkitt 
lymphoma (BL),” or “Burkitt-like lymphoma (BLL),” have over-
lapping clinical, morphological, and/or immunophenotypic fea-
tures belonging to diffuse large B-cell lymphoma (DLBCL) and 
BL. The 2008 WHO classification includes provisional borderline 
categories for cases that are not clearly DLBCL or BL. This new 
category is called as B-cell lymphoma, unclassifiable, with fea-
tures intermediate between DLBCL and BL (intermediate DLBCL/
BL) [4]. Many cases of intermediate DLBCL/BL that morphologi-
cally resemble BL occur in adults and are rare in patients under 
the age of 18 [5]. In general, these cases have a poor prognosis, 
with the exception of children. In children, intermediate DLBCL/
ISSN 2234-3806 • eISSN 2234-3814 Ahn JY, et al.
Gray zone lymphoma between DLBCL and BL
163 http://dx.doi.org/10.3343/alm.2012.32.2.162 www.annlabmed.org
BL does not have an adverse prognosis, based on gene expres-
sion profiling (GEP), although the number of patients studied is 
low. The prognosis for young adults is still unclear [6]. Herein, we 
report a case of intermediate DLBCL/BL in a Korean child and 
review the relevant literature. 
CASE REPORT
A 2-yr-old male was admitted for evaluation and management of 
left hip pain. On admission, physical examination was significant 
for several palpable lymph nodes in the left inguinal area and an 
ill-defined heterogeneous mass-like lesion in the left anterome-
dial muscle. Abdominopelvic computed tomography and mag-
netic resonance imaging of both hips were performed on suspi-
cion of myositis. Radiologic studies suggested osteomyelitis of 
the left proximal femur with subperiosteal abscess, myositis, and 
a small-cell tumor, such as lymphoma, leukemia, or Ewing’s 
sarcoma. Bone biopsy of the femur neck, bone marrow (BM) 
aspiration, and biopsy of both posterior superior iliac crests were 
performed. Immunohistochemistry on the biopsy specimen of 
the femur neck revealed tumor cells positive for CD20, CD10, 
BCL2, BCL6, CD99, and Ki67 (-90%) and negative for myeloper-
oxidase (MPO), Tdt, CD3, and cyclin D1 (Fig. 1). In situ hybrid-
ization for Epstein-Barr virus-encoded RNAs (EBER) was nega-
tive in the tumor cells. The final diagnosis from the bone biopsy 
was high-grade B-cell lymphoma, suggestive of B lymphoblastic 
lymphoma. Peripheral blood examination revealed the following: 
hemoglobin, 9.6 g/dL; white blood cell count, 6.83×10
9/L; plate-
let count, 182×10
9/L, and 5 atypical lymphocytes per 100 white 
blood cells. Based on the laboratory findings and bone biopsy 
results, we suspected lymphoma or lymphoblastic leukemia; 
therefore, we performed BM examination, cytogenetic analysis, 
and immunophenotyping. The BM biopsy was insufficient for 
evaluating cellularity; 49.3% of all nucleated cells were abnor-
mal lymphoid cells, consisting of large- and medium-sized cells. 
Large neoplastic cells had irregular nuclei with 1-2 distinct nu-
cleoli and abundant deeply basophilic cytoplasm. Medium-sized 
cells had round nuclei with 1-4 prominent nucleoli and scantly 
to moderately basophilic cytoplasm with some vacuoles (Fig. 2). 
Immunophenotyping of the neoplastic cells revealed positivity for 
CD45 (99.0%), CD19 (94.84%), CD10 (27.64%), CD20 (94.24%), 
HLA-DR (95.70%), sIg lambda (96.45%), CD13 (22.46%), and 
CD117 (22.22%) and negativity for CD34 (0.01%), Tdt (0.64%), 
MPO (0.01%), CD33 (1.58%), CD14 (1.18%), CD41 (3.08%), 
CD2 (3.00%), sCD3 (7.78%), CD5 (1.42%), CD7 (1.34%), and 
CD56 (5.82%). Cytogenetic analysis of the cells in the BM aspi-
rates revealed that the cells had the following karyotypes: 46,XY, 
t(8;14)(q24.1;q32),del(11)(q13),dup(11)(q22q13),der(17)del(17)
(p12)t(1;17)(q21;q25)[29]/46,idem,t(12;19)(q13;p13.2)[4]/46, 
idem,add(19))(p11)[4]/46,idem,add(13)(q34)[3] (Fig. 3). FISH 
analysis of BM aspirate cells was performed using Vysis LSI 
IGH/MYC, CEP 8 tri-color, dual fusion translocation probes (Ab-
bott Molecular, Des Plaines, IL, USA). We detected an IGH-MYC 
rearrangement in 81.2% of the nuclei examined with typical 2 
fusions, 1 orange, 1 green, and 2 aqua signals, which was de-
scribed as nuc ish (D8Z2x2,MYCx3,IGHx3)(MYC con IGHx2)
[325/400] (Fig. 4). Neither BCL2 nor BCL6 rearrangements were 
observed by FISH analysis on BM aspirates cells using Vysis LSI 
BCL2 and BCL6 dual color, break apart rearrangement probes 
(Abbott Molecular). The patient was diagnosed with intermedi-
ate DLBCL/BL. Intensive chemotherapy with prednisone, vin-
cristine, L-asparaginase, daunorubicin, and central nervous sys-
tem prophylaxis with intrathecal methotrexate (MTX) and cytara-
bine were initiated. One month after the initial diagnosis, follow-
Fig. 1. Immunohistochemistry shows positivity for BCL2 (A), BCL6 (B), CD10 (C), and Ki67 (D) of tumor cells (Femur neck, immunohisto-
chemical stains, 400× magnification).
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up BM examination demonstrated persistence of abnormal lym-
phoid cells. Cerebrospinal fluid (CSF) analysis was performed 
after induction of chemotherapy; CSF cytology, including cyto-
spin, showed atypical lymphoid cells consistent with malignant 
lymphoma. The patient was treated again with cyclophospha-
mide, vincristine, prednisone, adriamycin, MTX, and intrathecal 
MTX and cytarabine. The patient died of sepsis 5 months after 
initiation of the second round of chemotherapy.
DISCUSSION
Gray zone B-cell lymphoma, such as intermediate DLBCL/BL, 
cannot be classified into a single distinct disease entity. This 
new category of lymphoma has morphologic, immunopheno-
typic, and genetic features that include aspects of both DLBCL 
and BL, but differ with respect to one or more findings [7]. The 
2008 WHO classification affirms that the following lymphoma 
cases should not be diagnosed as intermediate DLBCL/BL: those 
Fig. 2. Bone marrow smear (A, Wright–Giemsa stain, 1,000× magnification) and biopsy (B, H&E stain, 1,000× magnification) reveal ab-
normal lymphoid cells composed of large and medium sized cells. Large neoplastic cells showed irregular nuclei with 1-2 distinct nucleoli 
and abundant deeply basophilic cytoplasm. Medium-sized cells showed round nuclei with 1-4 prominent nucleoli and had scantly to mod-
erately basophilic cytoplasm with some vacuoles.
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Fig. 3. Giemsa–trypsin banding showed the following karyotypes: 46,XY,t(8;14)(q24.1;q32),del(11)(q13),dup(11)(q22q13),der(17)del(17)
(p12)t(1;17)(q21;q25)[29]/46,idem,t(12;19)(q13;p13.2)[4]/46,idem,add(19))(p11)[4]/46,idem,add(13)(q34)[3].
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with a typical DLBCL morphology and a very high proliferation 
index, typical DLBCL with a MYC translocation, typical BL with-
out a MYC rearrangement, and those with IG-MYC rearrange-
ment as the only abnormality [4]. 
  Intermediate DLBCL/BL most often occurs in adults, some 
with a history of follicular lymphoma; it is extremely rare in pedi-
atric patients. The majority of patients present with generalized 
lymphadenopathy or mass lesions in extranodal sites and fre-
quent involvement of the BM. Some patients have a leukemic 
presentation [5, 8]. Liang et al. [8] reported the clinicopathologic 
features of 2 pediatric patients with gray zone lymphoma, who 
presented with common features, such as male gender, older 
than 10 yr of age at the time of diagnosis, and presentation with 
a mediastinal mass. In children, high cure rates are achieved with 
treatment strategies similar or identical to those for BL and DL-
BCL [9]. The gray zone between BL and DLBCL currently does 
not impact therapy decision or outcome in childhood lympho-
mas [7].
  Morphologic feature are useful in the differential diagnosis of 
intermediate DLBCL/BL. Such morphologic features include 
variable cellular forms, such as those smaller than typical DL-
BCL, those resembling BL cells, those larger than typical BL, 
and those resembling DLBCL cells. The immunophenotype is 
similar to BL, showing positivity for CD19, CD20, CD22, CD79a, 
and germinal center-associated molecules, CD10 and BCL6. 
BCL2 expression may be absent, weak, or strong, and the Ki67 
labeling index shows varying positivity [3]. Genetically, 35-50% of 
cases of intermediate DLBCL/BL show 8q24/MYC translocations 
but often with atypical features, including one or more of the fol-
lowing: (1) rearrangement with a non-IG partner, (2) part of a 
complex karyotype, and (3) concurrent rearrangements of the 
BCL2 and/or BCL6 genes, suggesting a “double-hit” or “triple-
hit” lymphoma. Double-hit lymphomas are characterized by a 
second translocation in addition to t(8;14), t(8;22), or t(2;8). In 
the majority of the double-hit cases, an 18q21/BCL2 breakpoint 
can be found, mostly as a t(8;14) plus t(14;18) karyotype [10-13]. 
Double-hit lymphomas are almost always absent in children, 
consistent with the almost complete lack of t(14;18) found among 
lymphomas in those younger than 18 yr [6]. 
  More recently, GEP analysis using microarrays can establish 
molecular categories within the gray zone between DLBCL and 
BL [1]. The bioinformatic core group extension method applied 
by the Molecular Mechanisms in Malignant Lymphomas group 
identified a set of 53 mature aggressive B-cell lymphomas with 
a molecular BL (mBL) index between that of mBL (mBL index 
>0.95) and that of non-mBL (mBL index  <0.05). These lym-
phomas could not be classified as mBL or as non-mBL and were 
called “molecular intermediate lymphomas” [1, 5, 6]. Molecular 
intermediate DLBCL/BL in children has a significantly higher 
Burkitt index by GEP than in adult patients, frequent IG-MYC 
positivity, and a good outcome. Interestingly, significant numbers 
(31%) of morphologic DLBCL in children show mBL by GEP, 
with more than half of them having IG-MYC. These findings sug-
gest that, in children, biologic BL might be hidden among DL-
BCL [6]. Salaverria et al. [6] suggested that GEP should be con-
sidered a single diagnostic criterion, like MYC status or CD10 
positivity. 
  In the present case, the patient was diagnosed with interme-
diate DLBCL/BL based on the intermediate morphological fea-
tures of both BL and DLBCL, the expression of CD10, BCL6, 
BCL2, and Ki67 labeling index, and a complex karyotype with 
8q34/MYC.
  Based on existing literature and the findings of this case, eval-
uation for intermediate DLBCL/BL should include an immuno-
phenotypic panel with CD10, BCL6, BCL2, and Ki67. In addition, 
evaluation should include conventional cytogenetic analysis for 
detection of simple or complex karyotypic abnormalities and 
molecular cytogenetic evaluation (FISH) with MYC-IgH fusion 
probe for t(8;14), BCL2-IgH fusion probe for t(14;18), BCL2 
break-apart probe, BCL6 break-apart probe, MYC break-apart 
probe, IGH break-apart probe, and IGL break-apart probe for 
t(2;8) and t(8;22) [12].
  However, several questions remain unanswered. A major con-
Fig. 4. FISH analysis using Vysis LSI IGH/MYC, CEP 8 tri-color, dual 
fusion translocation probe reveals IGH-MYC rearrangement with 2 
fusions (IGH-MYC fusions on der(8)t(8;14) and der(14)t(8;14)), 1 or-
ange (native MYC), 1 green (native IGH), and 2 aqua (D8Z2) signals.Ahn JY, et al.
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cern is that cases of intermediate DLBCL/BL only slightly differ 
from BL and DLBCL. Therefore, it is important that the diagnos-
tic border of DLBCL and BL is clearly defined in order to identify 
the specific morphology, immunophenotyping, genetics, and 
molecular lesions based on a gene expression. Another issue is 
that the current treatment of intermediate DLBCL/BL may com-
promise the validity of clinical trials evaluating the efficacy and 
safety of therapies on well-established diagnostic entities and 
may obscure the pathologic predictors of their outcome and treat-
ment response. 
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